The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 32 | — | 20.1x | Below average | |
Growth | 38 | -61.7% | 5.6% | Near average | |
Quality | 93 | 445.2% | 7.6% | Above average | |
Safety | 35 | -0.6x | 0.4x | Near average | |
Capital Return | 30 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Clene Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Clene Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Analysts' outlook for Clene stock has seen the price target stabilize at 50, although there has been a decrease in the number of analysts following the stock from 3 to 2 over the past 30 days. This contraction in the coverage base indicates a decline in institutional interest or a reassessment of risks, despite the announced recommendations remaining at a 'Buy' rating by major institutions such as Roth MKM and Benchmark.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.